Table 1.
Patient and tumor characteristics based on chemotherapy regimens with or without l-asparaginase.
| Non-l-ASP | l-ASP | p-value | ||
|---|---|---|---|---|
| N = 40 | N = 36 | |||
| N (%) | N (%) | |||
| Gender | Male | 24 (60.0 %) | 22 (61.1 %) | 1.00 |
| Female | 16 (40.0 %) | 14 (38.9 %) | ||
| Age | < 60 years | 29 (72.5 %) | 24 (66.7 %) | 0.62 |
| ≥ 60 years | 11 (27.5 %) | 12 (33.3 %) | ||
| Ann Arbor stage | I | 30 (75.0 %) | 23 (63.9 %) | 0.33 |
| II | 10 (25.0 %) | 13 (36.1 %) | ||
| B symptoms | 0 | 31 (77.5 %) | 28 (77.8 %) | 1.00 |
| 1 | 9 (22.5 %) | 8 (22.2 %) | ||
| Initial LDH | ≤ 225 IU/L | 22 (55.0 %) | 21 (58.3 %) | 1.00 |
| > 225 IU/L | 15 (37.5 %) | 14 (38.9 %) | ||
| Missing | 3 (7.5 %) | 1 (2.8 %) | ||
| RT dose | EQD2 ≥ 40 Gy | 36 (90.0 %) | 17 (47.2 %) | < 0.001 |
| EQD2 < 40 Gy | 4 (10.0 %) | 19 (52.8 %) | ||
| Response after CTx | CR | 25 (62.5 %) | 27 (75.0 %) | 0.32 |
| PR | 15 (37.5 %) | 9 (25.0 %) | ||
| RT technique | 3D-CRT | 34 (85.0 %) | 15 (41.7 %) | < 0.001 |
| IMRT | 6 (15.0 %) | 21 (58.3 %) |
l-ASP, l-asparaginase-containing chemotherapy; LDH, lactate dehydrogenase; RT, radiotherapy; EQD2, equivalent dose in 2 Gy fractions; CTx, chemotherapy; CR, complete response; PR, partial response; 3D-CRT, three-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy.